Patents Examined by Ilia I Ouspenski
  • Patent number: 10011656
    Abstract: The present invention is based, in part, on the identification of novel human anti-PD-1, PD-L1, and PD-L2 antibodies. Accordingly, the invention relates to compositions and methods for diagnosing, prognosing, and treating conditions that would benefit from modulating PD-1, PD-L1, and/or PD-L2 activity (e.g., persistent infectious diseases, autoimmune diseases, asthma, transplant rejection, inflammatory disorders and tumors) using the novel human anti-PD-1, PD-L1, and PD-L2 antibodies described herein.
    Type: Grant
    Filed: August 10, 2015
    Date of Patent: July 3, 2018
    Assignees: EMORY UNIVERSITY, DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Gordon J. Freeman, Rafi Ahmed, Timothy D. Jones, Francis J. Carr, James P. Gregson
  • Patent number: 9994817
    Abstract: Disclosed are methods for isolating, cultivating, and/or cells including regulatory T cells (Tregs). The methods typically include cultivating cells including Tregs in a culture media comprising a ligand for programmed cell death receptor (PD-1) conjugated to a solid support. Suitable ligands may include PD-L1 and suitable solid supports may include magnetic or paramagnetic beads where the methods further include removing the PD-L1/bead conjugates after the Tregs have been isolated, cultured, and/or expanded.
    Type: Grant
    Filed: August 7, 2015
    Date of Patent: June 12, 2018
    Assignee: Northwestern University
    Inventors: Joseph R. Leventhal, James M. Mathew, Lorenzo Gallon, M. Javeed Ansari
  • Patent number: 9994818
    Abstract: The invention includes compositions and methods for generating and expanding therapeutic Th17 cells. The invention includes contacting T cells with a composition comprising a first agent that is capable of providing a primary activation signal to T cells and a second agent that is capable of activating ICOS on T cells in the presence of Th-17 polarizing agents.
    Type: Grant
    Filed: August 11, 2015
    Date of Patent: June 12, 2018
    Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: James L. Riley, Chrystal Paulos, Carl H. June, Bruce L. Levine
  • Patent number: 9987500
    Abstract: The present invention provides antibodies that bind to the T-cell co-inhibitor programmed death-1 (PD-1) protein, and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that bind to PD-1. In certain embodiments, the present invention provides multi-specific antigen-binding molecules comprising a first binding specificity that binds to PD-1 and a second binding specificity that binds to an autoimmune tissue antigen, another T-cell co-inhibitor, an Fc receptor, or a T-cell receptor. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing PD-1 activity, thus providing a means of treating a disease or disorder such as cancer or a chronic viral infection. In other embodiments, the antibodies are useful for enhancing or stimulating PD-1 activity, thus providing a means of treating, for example, an autoimmune disease or disorder.
    Type: Grant
    Filed: January 23, 2015
    Date of Patent: June 5, 2018
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Nicholas J. Papadopoulos, Andrew J. Murphy, Gavin Thurston, Ella Ioffe, Elena Burova
  • Patent number: 9988450
    Abstract: Provided are antibodies that specifically bind to Programmed Death-1 (PD1, Pdcd-1, or CD279) and inhibit PD1-mediated cellular signaling and activities in immune cells, antibodies binding to a set of amino acid residues required for its ligand binding, and uses of these antibodies to treat or diagnose cancer, infectious diseases or other pathological disorders modulated by PD1-mediated functions.
    Type: Grant
    Filed: November 2, 2017
    Date of Patent: June 5, 2018
    Assignee: BEIGENE SWITZERLAND GMBH
    Inventors: Kang Li, Tong Zhang, Jing Song, Lanlan Xu, Qi Liu, Hao Peng
  • Patent number: 9982051
    Abstract: A pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS that does not include the autoimmune neuroinflammatory disease, relapsing-remitting multiple sclerosis (RRMS), is provided. The pharmaceutical composition is for administration by a dosage regimen comprising at least two courses of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session of non-treatment.
    Type: Grant
    Filed: November 22, 2017
    Date of Patent: May 29, 2018
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: Michal Eisenbach-Schwartz, Kuti Baruch, Neta Rosenzweig
  • Patent number: 9982047
    Abstract: A pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS that does not include the autoimmune neuroinflammatory disease, relapsing-remitting multiple sclerosis (RRMS), is provided. The pharmaceutical composition is for administration by a dosage regimen comprising at least two courses of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session.
    Type: Grant
    Filed: November 22, 2017
    Date of Patent: May 29, 2018
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: Michal Eisenbach-Schwartz, Kuti Baruch, Neta Rosenzweig
  • Patent number: 9982048
    Abstract: A pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS that does not include the autoimmune neuroinflammatory disease, relapsing-remitting multiple sclerosis (RRMS), is provided. The pharmaceutical composition is for administration by a dosage regimen comprising at least two courses of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session.
    Type: Grant
    Filed: November 22, 2017
    Date of Patent: May 29, 2018
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: Michal Eisenbach-Schwartz, Kuti Baruch, Neta Rosenzweig
  • Patent number: 9982049
    Abstract: A pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS that does not include the autoimmune neuroinflammatory disease, relapsing-remitting multiple sclerosis (RRMS), is provided. The pharmaceutical composition is for administration by a dosage regimen comprising at least two courses of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session.
    Type: Grant
    Filed: November 22, 2017
    Date of Patent: May 29, 2018
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: Michal Eisenbach-Schwartz, Kuti Baruch, Neta Rosenzweig
  • Patent number: 9982050
    Abstract: A pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS that does not include the autoimmune neuroinflammatory disease, relapsing-remitting multiple sclerosis (RRMS), is provided. The pharmaceutical composition is for administration by a dosage regimen comprising at least two courses of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session.
    Type: Grant
    Filed: November 22, 2017
    Date of Patent: May 29, 2018
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: Michal Eisenbach-Schwartz, Kuti Baruch, Neta Rosenzweig
  • Patent number: 9975950
    Abstract: The present invention provides antibodies directed against ICOS or a derivative thereof which neutralize ICOS engagement on Treg by inhibiting the fixation between ICOS and ICOS-L and abrogate proliferation of Treg induced by plasmacytoid dendritic cells. The present invention further provides antibodies directed against ICOS or a derivative thereof which induce IL-10 and IFN? production, induce CD4+ T cells proliferation, reduce Tconv proliferation, and increase the immunosuppressive function of Treg.
    Type: Grant
    Filed: April 20, 2017
    Date of Patent: May 22, 2018
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), INSTITUT JEAN PAOLI & IRENE CALMETTES, UNIVERSITE D'AIX-MARSEILLE, Universite Claude Bernard—Lyon 1, Centre Leon Berard
    Inventors: Julien Faget, Christophe Caux, Christine Menetrier-Caux, Jacques Nunes, Daniel Olive
  • Patent number: 9974845
    Abstract: The present invention relates to a vaccine/inhibitor combination comprising an RNA vaccine comprising at least one RNA comprising at least one open reading frame (ORF) coding for at least one antigen and a composition comprising at least one PD-1 pathway inhibitor, preferably directed against PD-1 receptor or its ligands PD-L1 and PD-L2. The present invention furthermore relates to a pharmaceutical composition and a kit of parts comprising the components of such a vaccine/inhibitor combination. Additionally the present invention relates to medical use of such a vaccine/inhibitor combination, the pharmaceutical composition and the kit of parts comprising such a vaccine/inhibitor combination, particularly for the prevention or treatment of tumor or cancer diseases or infectious diseases. Furthermore, the present invention relates to the use of an RNA vaccine in therapy in combination with a PD-1 pathway inhibitor and to the use of a PD-1 pathway inhibitor in therapy in combination with an RNA vaccine.
    Type: Grant
    Filed: February 21, 2014
    Date of Patent: May 22, 2018
    Assignee: CureVac AG
    Inventors: Mariola Fotin-Mleczek, Karl-Josef Kallen, Jochen Probst
  • Patent number: 9963508
    Abstract: In accordance with the present invention, there are provided fully human monoclonal antibodies against human cytotoxic T-lymphocyte antigen 4 (CTLA-4). Nucleotide sequences encoding and amino acid sequences comprising heavy and light chain immunoglobulin molecules, particularly contiguous heavy and light chain sequences spanning the complementarity determining regions (CDRs), specifically from within FR1 and/or CDR1 through CDR3 and/or within FR4, are provided. Further provided are antibodies having similar binding properties and antibodies (or other antagonists) having similar functionality as antibodies disclosed herein.
    Type: Grant
    Filed: October 20, 2014
    Date of Patent: May 8, 2018
    Assignees: AMGEN FREMONT INC., PFIZER INC.
    Inventors: Douglas Charles Hanson, Mark Joseph Neveu, Eileen Elliott Mueller, Jeffrey Herbert Hanke, Steven Christopher Gilman, C. Geoffrey Davis, Jose Ramon Corvalan
  • Patent number: 9963497
    Abstract: The present disclosure relates to a method for the treatment of a non-pathogen associated inflammatory disorders in a subject in need thereof, comprising administering to said subject an isolated peptide which specifically binds to an amino acid sequence within the dimer interface of a T cell costimulatory pathway member, particularly the T cell costimulatory pathway members CD28 and CTLA4. The present disclosure also relates to pharmaceutical compositions comprising the isolated peptide and to use of the peptide in treating of a non-pathogen associated inflammatory disorders.
    Type: Grant
    Filed: December 7, 2014
    Date of Patent: May 8, 2018
    Assignees: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD, ATOX BIO LTD.
    Inventors: Raymond Kaempfer, Anat Shirvan, Gila Arad
  • Patent number: 9957323
    Abstract: Antibodies that bind ICOS (Inducible T cell Co-Stimulator). Therapeutic use of anti-ICOS antibodies for modulating the ratio between regulatory T cells and effector T cells, to stimulate the immune system of patients, including use in treating cancers. Methods of producing anti-ICOS antibodies, including species cross-reactive antibodies, using transgenic knock-out mice.
    Type: Grant
    Filed: September 7, 2017
    Date of Patent: May 1, 2018
    Assignee: Kymab Limited
    Inventors: Richard Charles Alfred Sainson, Stephen John Arkinstall, Jamie Iain Campbell, Mohammed Hanif Ali, E-Chiang Lee, Matthew John McCourt, Nikole Sandy, Cassandra Van Krinks, Volker Germaschewski, Ian Kirby, Miha Kosmac, Thomas Gallagher, Cecilia Deantonio, Stephen D. Gillies
  • Patent number: 9938345
    Abstract: The present invention provides antibodies that bind to the T-cell co-inhibitor ligand programmed death-ligand1 (PD-L1) protein, and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that bind to PD-L1. In certain embodiments, the present invention provides multi-specific antigen-binding molecules comprising a first binding specificity that binds to PD-L1 and a second binding specificity that binds to a tumor cell antigen, an infected cell-specific antigen, or a T-cell co-inhibitor. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing PD-L1 activity, thus providing a means of treating a disease or disorder such as cancer or viral infection.
    Type: Grant
    Filed: January 23, 2015
    Date of Patent: April 10, 2018
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Nicholas J. Papadopoulos, Andrew J. Murphy, Gavin Thurston, Ella Ioffe, Elena Burova
  • Patent number: 9868790
    Abstract: The present invention relates to anti-human OX40L antibodies, new medical uses and methods.
    Type: Grant
    Filed: July 27, 2017
    Date of Patent: January 16, 2018
    Assignee: Kymab Limited
    Inventors: Philip Bland-Ward, Miha Kosmac, Steve Holmes, Ian Kirby, Jamie Campbell
  • Patent number: 9862767
    Abstract: The present disclosure relates to anti-CD200 antibodies and to use of the antibodies in methods for treating autoimmune disorders and cancer. Also featured are biomarkers for use in selecting or prescribing a treatment modality for a patient with an autoimmune disorder and/or cancer. In addition, the disclosure features methods of treatment using an anti-CD200 antibody in combination with one or more additional therapeutic agents such as an anti-CD20 therapeutic agent.
    Type: Grant
    Filed: June 15, 2015
    Date of Patent: January 9, 2018
    Assignee: Alexion Pharmaceuticals, Inc.
    Inventors: Russell P. Rother, Yan Yan